Clinical trial tests frankincense as potential breast, colon cancer treatment

NewsGuard 100/100 Score

Cancer surgeon and researcher Nancy DeMore is leading a clinical trial using frankincense to try to treat breast and colon cancer at the Medical University of South Carolina. The study was inspired by a research specialist in DeMore's lab.

Ingrid Bonilla had researched frankincense as a treatment on breast cancer cells as an undergraduate student at Charleston Southern University. "Seeing encouraging results in our lab, I did my research on clinical studies with frankincense. I contacted the author of the only published breast cancer clinical case study to find out more."

DeMore, who has done extensive research on new treatments for breast cancer, was willing to put it to the test. "It's nice to see doctors like her who think outside the box," Bonilla says. "Out of all the physicians that I talked to about this, Dr. DeMore was the only one who was interested in moving this forward."

DeMore says boswellic acid, the extract from Indian frankincense, may help patients by reducing inflammation. The chemical structure of boswellic acid is similar to other anti-inflammatory drugs such as ibuprofen. Bonilla and DeMore wrote the current clinical trial with data from clinical trials of the extract in Europe.

DeMore says their study is "window of opportunity" trial that takes advantage of the window of time between the initial diagnosis of breast or colon cancer and surgery to remove the cancer. The patient will take boswellia while waiting for surgery.

"Tumor from the biopsy that was taken to make the diagnosis of cancer before treatment will be is compared to the tumor taken at surgery after treatment," DeMore said. "This will allow us to assess whether taking boswellia changes the biology of the tumor."

Frankincense would not be the only plant-based treatment for illness. For example, digoxin, from the foxglove plant, is used to treat cardiac arrhythmias. DeMore says it's important to put potential treatments through rigorous testing. "A lot of herbs and alternative therapies haven't been studied scientifically, so it's really important to know, in a well-designed clinical trial, these natural products work."

DeMore started her research into natural products with curcumin in the 1990s. Extracted from turmeric, curcumin inhibits blood vessel growth in tumors. Slowing the growth of new blood vessels in tumors is a common approach to treating many cancers.

DeMore then set out to test medicinal uses of other natural products. "What we are really committed to doing is to study natural products in a well-designed clinical trial to prove whether or not there is a benefit. We don't know if it's going to work."

The MUSC Hollings Cancer Center is funding the trial.

While the preclinical evidence for boswellic acid seems promising, it's important not to replace standard treatment with natural therapies that haven't been studied well, Demore says. "The traditional treatments that we advise for patients have been through extensive, rigorous clinical trials where the benefits of treatment are well-known, as are the side effects."

She says therapies that aren't based on clinical trial results could have unexpected side effects, or even harmful effects. She also says people should be aware that over-the-counter frankincense may not contain the dosage or quality of the extract being tested in this study.

Bonilla is just grateful that DeMore took her idea seriously. "Sometimes I'm, like, 'Wow! I never pictured myself five years ago sitting here and being involved in anything like this.' I consider myself very blessed," she says.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer